Menu

Report Library

All Reports

Early 2016 Outlook Report

February 05, 2016

In this report, we cover catalysts from 22 drugs, devices and diagnostics expected to occur in early 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through early 2016 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Q4 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 6 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 75% of catalyst outcomes that occurred in Q4 2015.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Acute Myelogenous Leukemia (AML)
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))
Cardiac Valve Surgery
Chemotherapy Induced Nausea and Vomiting (CINV)
Coronary Artery Disease
Dyslipidemia / Hypercholesterolemia
Endometriosis
Hepatic Fibrosis
HIV / AIDS Treatment
Hyperparathyroidism (Secondary)
Indolent Non-Hodgkin's Lymphoma - iNHL
Migraine and Other Headaches
Multiple Myeloma (MM)
Osteoarthritis
Osteoporosis / Osteopenia
Parkinson's Disease (PD)
Peripheral Arterial Disease (PAD)
Psoriasis
Rheumatoid Arthritis (RA)
Substance Use Disorder
Venous Thromboembolism (VTE)

 Additional Resources: